{"nct_id":"NCT06982521","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-08-26","start_date_type":"ACTUAL","primary_completion_date":"2028-04-30","primary_completion_date_type":"ESTIMATED","completion_date":"2031-12-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["RLAY"]}